NIH Launches First National Phage Therapy Research Network to Accelerate Treatments Against Antibiotic-Resistant Superbugs

-

Media contact: HSNews@pitt.edu

As antimicrobial resistance continues to rise worldwide, bacteriophage therapy is increasingly being viewed as one of the most promising alternatives to conventional antibiotics. While numerous compassionate-use cases and early clinical studies have demonstrated the potential of phages to treat multidrug-resistant infections, the field still faces significant scientific and regulatory challenges. A major obstacle has been the lack of standardized tools capable of predicting how phages behave in the human body, how they should be formulated, and how therapeutic cocktails can be optimized for clinical use.

© www.medschool.pitt.edu

To address these challenges, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has established the first coordinated national research network dedicated specifically to advancing phage therapeutics. Through its new Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens program, known as CAPT-CEP, NIAID has brought together three multidisciplinary research centers tasked with developing the preclinical foundations needed to transform phage therapy from an experimental intervention into a reliable and scalable medical technology.

The initiative focuses on the ESKAPE pathogens, a group of bacterial species responsible for a large proportion of hospital-acquired infections worldwide. These organisms include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species. Collectively, they represent some of the most problematic multidrug-resistant pathogens encountered in modern healthcare and are frequently associated with treatment failure, prolonged hospitalization and increased mortality.

Although bacteriophages offer a highly targeted method for eliminating these pathogens, important knowledge gaps remain. Unlike conventional antibiotics, phages are biological entities capable of replication, evolution and complex interactions with both bacteria and host tissues. Understanding their pharmacokinetics, tissue distribution, dosing strategies and long-term therapeutic performance requires entirely new experimental frameworks.

One of the newly funded centers, the Center for PhAIge Therapy at the Gladstone Institutes, is approaching the problem from an engineering perspective. Led by Seth Shipman, the program aims to break phages down into functional biological modules and use advanced computational approaches to predict their behavior against Klebsiella pneumoniae. The center combines high-throughput experimental platforms, deep-learning algorithms and human organoid systems to better understand and eventually design phages with predictable therapeutic properties.

At Stanford University, the Center for Phage Pharmaceuticals is focusing on a different but equally important challenge: phage pharmacology. Directed by Paul Bollyky, the program is investigating how therapeutic phages move through the body, how long they persist, and how efficiently they reach infected tissues. Researchers are integrating nuclear medicine imaging technologies with advanced animal models and respiratory cell culture systems to optimize phage delivery against Pseudomonas aeruginosa, a major pathogen affecting individuals with cystic fibrosis. Because phages can replicate directly at sites of infection, their pharmacokinetic behavior differs fundamentally from that of traditional drugs, making these studies particularly important for future clinical development.

The University of Pittsburgh's Center for Accelerating Phage Therapy brings yet another dimension to the network. Co-directed by Daria Van Tyne and Alexander Sulakvelidze, the center focuses on developing standardized assays capable of improving phage cocktail design, efficacy testing and dosing strategies. Researchers are leveraging biospecimens collected from dozens of phage therapy patients, together with clinical data generated through compassionate-use treatments and ongoing trials. The program also benefits from collaboration with Intralytix, one of the longest-standing companies involved in therapeutic phage development, creating a direct bridge between academic research and industrial translation.

One of the most significant aspects of the CAPT-CEP initiative is its emphasis on collaboration. Rather than operating independently, the three centers will share methodologies, reference materials and experimental data through regular scientific exchange. Researchers are also exploring the creation of a centralized database hosted by the National Center for Biotechnology Information, potentially establishing one of the largest standardized repositories of phage therapy data ever assembled.

The scale of the investment reflects growing recognition of phage therapy as a strategic component of future antimicrobial medicine. NIAID has allocated approximately six million dollars during fiscal year 2026 to support the program, with each center eligible to receive up to 1.2 million dollars annually over a five-year period. Beyond the immediate funding, the initiative signals a broader shift in how phage therapy is being approached within the United States. The field is moving away from isolated compassionate-use success stories toward a more systematic framework built on reproducible science, standardized methodologies and regulatory readiness.

For the phage therapy community, the creation of CAPT-CEP represents a significant milestone. The challenge is no longer demonstrating that phages can kill antibiotic-resistant bacteria. Numerous studies have already established that principle. The next step is building the scientific infrastructure required to make phage therapy predictable, scalable and accessible to patients on a much larger scale. By bringing together expertise in synthetic biology, pharmacology, computational modeling, clinical microbiology and translational medicine, the new network may help accelerate that transition.

As antibiotic resistance continues to threaten healthcare systems worldwide, initiatives such as CAPT-CEP illustrate how phage therapy is evolving from a niche research field into a coordinated scientific discipline capable of supporting future therapeutic development. The coming years will determine whether these efforts can provide the robust evidence base needed to integrate phages into mainstream infectious disease medicine.

Source : https://www.niaid.nih.gov/, https://www.pitt.edu/pitt-center-part-first-nih-funded-coordinated-research-network-phage-therapeutics

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more